RxDoctor Payments Data

Amy Wiegandt, MD

Internal Medicine · Wareham, MANPI 1285692525

Payments from drug & device makers

$1,292in general payments, 2019–2025

Across 63 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$180
  • AbbVie$173
  • GSK$162
  • Amgen$136
  • AstraZeneca$93
  • Boehringer Ingelheim$92
  • plus $455 from 14 others

What the payments were for

  • Food & beverage$1,292100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,292 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$369,630
Medicare patients
351
Services billed
5,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban106$109,172
OzempicSemaglutide73$99,376
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$24,456
Breo ElliptaFluticasone/Vilanterol21$22,928
XareltoRivaroxaban18$21,108
Tresiba Flextouch U-100Insulin Degludec17$15,449
EntrestoSacubitril/Valsartan11$11,226
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$9,623
Rosuvastatin Calcium228$8,814
Metoprolol Succinate249$5,972
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$5,086
Atorvastatin Calcium344$4,496
Omeprazole223$3,376
Albuterol Sulfate HfaAlbuterol Sulfate86$3,085
Losartan Potassium259$3,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$180$109,172106 claims
Novo NordiskOzempic$49$99,37673 claims
GSKTrelegy Ellipta, Breo Ellipta$162$47,38343 claims
Johnson & JohnsonXarelto$59$21,10818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Wareham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →